Taltz(ixekizumab)
Taltz (ixekizumab) is an antibody pharmaceutical. Ixekizumab was first approved as Taltz on 2016-03-22. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. The pharmaceutical is active against interleukin-17A.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Taltz
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Ixekizumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Taltz | ixekizumab | Eli Lilly | N-125521 RX | 2016-03-22 | 2 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| taltz | Biologic Licensing Application | 2021-03-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| psoriasis | EFO_0000676 | D011565 | L40 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
51 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 2 | 1 | 12 | 3 | 3 | 21 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | — | 4 | 2 | — | 6 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 2 | 1 | — | 1 | — | 4 |
| Spondylarthritis | D025241 | — | — | 3 | 1 | — | 4 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | — | — | 1 | — | — | 1 | |
| Juvenile arthritis | D001171 | EFO_0002609 | M08 | — | — | 1 | — | — | 1 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | 1 | — | — | 1 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
| Pityriasis rubra pilaris | D010916 | L44.0 | — | 1 | — | — | — | 1 | |
| Pyoderma gangrenosum | D017511 | EFO_0006835 | L88 | — | 1 | — | — | — | 1 |
| Bullous pemphigoid | D010391 | EFO_0007187 | L12 | — | 1 | — | — | — | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | IXEKIZUMAB |
| INN | ixekizumab |
| Description | Ixekizumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >6NOV:A,C|Fab Heavy Chain
QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAY
MELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW
NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH
>6NOV:B,D|Fab Light Chain
DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKI
SRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ
SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 6NOU, 6NOV |
| CAS-ID | 1143503-69-8 |
| RxCUI | 1745099 |
| ChEMBL ID | CHEMBL1743034 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB11569 |
| UNII ID | BTY153760O (ChemIDplus, GSRS) |
Target
Agency Approved
IL17A
IL17A
Organism
Homo sapiens
Gene name
IL17A
Gene synonyms
CTLA8, IL17
NCBI Gene ID
Protein name
interleukin-17A
Protein synonyms
CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, cytotoxic T-lymphocyte-associated protein 8, interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8), interleukin-17
Uniprot ID
Mouse ortholog
Il17a (16171)
interleukin-17A (Q62386)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Taltz - Eli Lilly
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,996 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15,177 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more